Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
نویسندگان
چکیده
AIM To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis. METHODS Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI). Patients were stratified by weight (<80 kg or ≥80 kg) and BMI (healthy, BMI 22 - 24.99 kg/m2; overweight, BMI 25 - 29.99 kg/m2; obese, BMI ≥30 kg/m2). RESULTS The study included 66 patients. Body weight had no effect on etanercept efficacy. There was a significant reduction in etanercept efficacy in obese patients (n = 12) compared with healthy weight (n = 33) or overweight (n = 21) patients. CONCLUSION Obesity has a negative effect on the efficacy of etanercept in psoriasis.
منابع مشابه
Cardiovascular risk factors in patients with psoriasis: A casecontrol study
Recent studies suggest that psoriasis may be an independent risk factor for the development of cardiovascular diseases. Myocardial infarction, pulmonary embolism, diabetes mellitus,hypertension, and dyslipidemia have been reported in patients with psoriasis Certain risk factors for cardiovascular diseases may be more prevalent among patients with psoriasis 3,4. The aim of this study was to defi...
متن کاملEfficacy of Cognitive-Behavioral Interventions in Weight Loss of People with Body Mass Index of 30 or Above (Obesity)
Objective: Obesity is a major health problem. Nowadays approximately one-third of the world population suffer from obesity which is frequently accompanied with serious medical and emotional problems. Three main evidence-based options exist for the treatment of obese individuals: lifestyle modification, pharmacotherapy, and bariatric surgery. The purpose of this study was to ...
متن کاملA prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate to-severe chronic plaque-type psoriasis: the Psoriasis Infiximab vs. Etanercept Comparison Evaluation (PIECE) study
There are no direct comparison data between infliximab and entanercept in the treatment of psoriasis. This study was a mult icenter, randomised control trial done in the Netherlands to compare the efficacy, outcome of etanercept vs. infliximab in the management of moderate to severe chronic plaque psoriasis. Patients (age 1875 years old) with Psoriasis Area and Severity Index (PASI) ≥10 and/or ...
متن کاملEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
BACKGROUND Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which tumour necrosis factor, a proinflammatory cytokine, is present in increased concentrations in joints and in the skin. Therefore, psoriatic arthritis and psoriasis may be appropriate therapeutic targets for etanercep...
متن کاملThe treatment of psoriasis with etanercept: An experience from South Kuwait
The Gulf Journal of Dermatology and Venereology ABSTRACT Background: Etanercept, a tumor necrosis factor antagonist, is an approved biologic agent for treatment of chronic plaque psoriasis in the United States and Europe. Objective: To observe the efficacy and safety profile of etanercept in patients with moderate to severe plaque psoriasis. Methods: In this retrospective study, 56 patients wer...
متن کامل